Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The enantiomer patent expires in July 2010.
Subscribe to our email newsletter
The patent was challenged jointly by generic companies Laboratorios Cinfa, Kern Pharma, Laboratorios Alter and Laboratorios Belmac and is one of four separate challenges to the enantiomer patent by generic companies in Spain. Lipitor is sold in Spain under the brand names Zarator and Cardyl. Cinfa, Kern, Alter and Belmac can seek to appeal the decision to the Supreme Court of Spain.
Peter Richardson, senior vice president at Pfizer, said: “This is a victory not only for Pfizer, but for all innovators pursuing high-risk medical discoveries and for the patients who benefit from those discoveries.”